Merck & Co
Merck & Co., Inc. (NYSE: MRK), also known as Merck Sharp & Dohme or MSD outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The headquarters of the company is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township. The company was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and then set up as an independent company. Currently, it is one of the seven largest pharmaceutical companies in the world both by market capitalization and revenue.
Campaign Finance$26,866,430 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
state-level data is not available in bulk for 2014. for current state data, browse http://followthemoney.org/
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Merck & Co
Names of Lobbyists
Firm Hired Amount Merck & Co $96,169,804 Schering-Plough Corp $1,810,000 Ruder Finn Inc $0
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
- Medical Research & Clin Labs,
- Consumer Product Safety,
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.2900 Food and Drug Administration Amendments Act of 2007 S.1082 Medical Device User Fee Amendments of 2007 S.301 Physician Payments Sunshine Act of 2009 S.515 Patent Reform Act of 2009 H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act H.R.6331 Medicare Improvements for Patients and Providers Act of 2008 H.R.452 Medicare Decisions Accountability Act of 2011 H.R.1260 Patent Reform Act of 2009
RegulationsMentioned in 290 dockets; Submitted to 52 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Merck & Co" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Merck & Co
- Toggle 2 FDA Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling 2006
- Toggle 2 FDA Guidance for Industry on Developing Products for Weight Management 2007
- Toggle 2 FDA Draft Guidance for Industry on Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment 2010
- Toggle 2 FDA Electronic Signatures: Time Stamps 2000
- Toggle 1 FDA Disclosure of Materials Provided to Advisory Committees 1999
- Toggle 1 SEC Comments on Proposed Rule: Acceleration of Periodic Report Filing Dates and Disclosure Concerning Website Access to Reports 2002
- Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Elemental Impurities; Availability 2013
- Toggle 1 FDA Patent Term Extension Application for ZIOPTAN® (tafluprost), U.S. Patent No. 5,886,035 2013
- Toggle 1 FDA Financial Disclosure By Clinical Investigators 1999
- Toggle 1 FDA Disclosure of Conflicts of Interest for Special Government Employees 2002
Mentions in Document Text
View all mentions data for Merck & Co
- Toggle 22 EPA Industrial Combustion Coordinated Rulemaking FACA 2004
- Toggle 6 EPA Pollution Prevention Strategy  2005
- Toggle 4 FDA Confirm that FDA Will Stay Approval of ANDA No. 90-040 for 30 Months from November 24, 2009 2010
- Toggle 4 EPA Pennsylvania- VOC and NOx RACT Determinations for Five (5) Individual Sources 2006
- Toggle 4 FDA Patent Extension for Invanz (ertapenem sodium), 5,478,820 2003
- Toggle 3 EPA Inventory Update Rule Amendments (IURA) 2002
- Toggle 3 EPA Prevention of Significant Deterioration (PSD) and Non-Attainment New Source Review (NSR): Baseline Emissions Determination, Actual-to-Future-Actual Methodology, Plantwide Applicability Limitations, Clean Units, Pollution Control Projects (Reconsideration) 2001
- Toggle 3 EPA Drinking Water Phase II Material Retained at the USEPA Office of Water Docket 2004
- Toggle 3 FDA International Conference on Harmonisation; Draft Guidance on M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk; Availability 2013
- Toggle 3 FDA Patent Extension Application for PREVICOX (firocoxib), U. S. Patent No. 5,981,576 2006
Contractor Misconduct18 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Health||None||Nationwide Vioxx Settlement||2007||Settlement||$4,850,000,000|
|Health||None||Nominal Pricing Fraud||2008||Settlement||$650,000,000|
|Health||None||Nationwide Vioxx Joint Civil-Criminal Settlement (Civil)||2011||Settlement||$628,364,000|
|Health||None||Nationwide Vioxx Joint Civil-Criminal Settlement (Criminal)||2011||Settlement||$321,636,000|
|Cost/Labor Mischarge||None||Medco False Claims Act Litigation||2006||Settlement||$137,500,000|
|Health||None||Barnett v. Merck (Vioxx Litigation)||2006||Judgment Against Defendant||$51,000,000|
|Health||None||Humeston v. Merck & Co., Inc. (Vioxx Litigation)||2007||Judgment Against Defendant||$47,500,000|
|Health||None||Medco ERISA Class Action Settlement||2002||Settlement||$42,500,000|
|Consumer Affairs||None||Medco Drug Switching Settlement||2004||Settlement||$29,300,000|
|Antitrust||None||Hawaii Average Wholesale Price Litigation||2010||Settlement||$28,000,000|
EPA Violations5 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Air Products & Chemical, Inc Et Al||Merck & Co., Inc (+40 others)||2005||Elkton, Md||$24,500,000|
|3m Company||Merck & Co., Inc. (+106 others)||2008||Wood Ridge, Nj||$18,000,000|
|Agere Systems, Et Al||Merck & Co., Inc. (+138 others)||2007||Elkton, Md||$11,300,000|
|3m Company Et Al.||Merck & Co., Inc. (+67 others)||2004||Carlstadt, Nj||$8,649,902|
|Benjamin Moore & Co., Et Al||Merck & Co Inc (+26 others)||2001||Piscataway, Nj||$2,000,000|
Advisory Committees11 people on 11 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Merck & Co" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 9 people on 9 committees
- Toggle Department of Defense 1 person on 1 committee
- Toggle National Science Foundation 1 person on 1 committee